Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Postgrad Med J ; 97(1148): 351-354, 2021 Jun.
Article in English | MEDLINE | ID: mdl-32554543

ABSTRACT

PURPOSE OF THE STUDY: The aim of our study was to investigate potential adverse reactions in healthcare professionals working in Level 3 barrier protection personal protective equipment (L3PPE) to treat patients with COVID-19. STUDY DESIGN: By using a convenience sampling approach, 129 out of 205 randomly selected healthcare professionals from the First Affiliated Hospital of Zhejiang University School of Medicine were invited to take part in a WeChat messaging app survey, Questionnaire Star, via a survey link. Healthcare personnel details were collected, including profession, years of professional experience and adverse reactions while wearing L3PPE. Survey results were divided by profession and years of professional experience; differences in adverse reactions were compared. RESULTS: Among the 129 healthcare professionals surveyed, 21 (16.28%) were doctors and 108 (83.72%) were nurses. A total of 122 (94.57%) healthcare professionals experienced discomfort while wearing L3PPE to treat patients with COVID-19. The main reasons for adverse reactions and discomfort include varying degrees of adverse skin reactions, respiratory difficulties, heat stress, dizziness and nausea. Doctors had a lower incidence of rashes (χ2=4.519, p=0.034) and dizziness (χ2=4.123, p=0.042) when compared with nurses. Junior (8.5 years of experience or fewer) healthcare personnel also experienced a higher rate of heat stress when compared with senior personnel (more than 8.5 years greater) (χ2=5.228, p=0.022). CONCLUSION: More attention should be offered to healthcare personnel wearing L3PPE to treat patients with COVID-19 because they are susceptible to developing adverse reactions.


Subject(s)
COVID-19/prevention & control , Health Personnel/statistics & numerical data , Infection Control/instrumentation , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Occupational Diseases/epidemiology , Personal Protective Equipment/adverse effects , Adult , Aged , COVID-19/transmission , Female , Humans , Male , Middle Aged , Surveys and Questionnaires
2.
Sichuan Da Xue Xue Bao Yi Xue Ban ; 49(3): 358-363, 2018 May.
Article in Chinese | MEDLINE | ID: mdl-30014634

ABSTRACT

OBJECTIVE: To explore the effect of silencing lumican on the invasion and migration of liver cancer cells. METHODS: Lumican was silenced by shRNA in liver cancer cells (HepG2 and MHCC97H). The mRNA levels of lumican were detected by qRT-PCR. Cell invasion was measured by Transwell. Cell migration was tested via wound healing. The protein levels of lumican,MMP-9,VEGF,ERK1,JNK,p-ERK1 and p-JNK were measured by Western blot. RESULTS: Liver cancer cells (HepG2 and MHCC97H) had higher levels of mRNA and protein of lumican compared with normal hepatocyte L02 (P<0.01). shRNA lowered the levels of mRNA and protein of lumican (P<0.01),and weakened the invasion and migration of cancer cells (P<0.01). The expressions of MMP-9 and VEGF decreased with the shRNA silence (P<0.01). shRNA also reduced the protein level of p-ERK1 and p-JNK (P<0.01). CONCLUSION: Silencing lumican by shRNA attenuates the invasion and migration of liver cancer cells via inhibiting the activation of ERK1/JNK pathway.


Subject(s)
Cell Movement , Gene Silencing , Liver Neoplasms/pathology , Lumican/metabolism , Neoplasm Invasiveness , Cell Line, Tumor , Humans , Liver Neoplasms/genetics , Lumican/genetics , MAP Kinase Kinase 4/metabolism , Matrix Metalloproteinase 9/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , RNA, Small Interfering , Vascular Endothelial Growth Factor A/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...